Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
+0.09 (+0.05%)
4:54:26 PM EDT: $171.80 -0.08 (-0.05%)
Products, Regulatory

Janssen Announces Results From Phase 3 MAIA Study

Published: 06/12/2021 11:32 GMT
Johnson & Johnson (JNJ) - Janssen Announces Results From Phase 3 Maia Study.
Janssen- Phase 3 Maia Study Shows Significant Overall Survival Benefits for Treatment With Darzalex® (daratumumab) in Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible.
Janssen-after Nearly 5 Years of Follow-up, Median Progression-free Survival Was Not Reached, and a Significant Overall Survival Benefit Was Observed.
Janssen - Data Will Be Presented As a Late-breaking Abstract at European Hematology Association (eha) Virtual Congress.